|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Neuropathic Pain - Comparative Overview of Treatment Preferences Across the Seven Major Markets
Datamonitor, May 2004, Pages: 178
Introduction
Following the success of Pfizer's blockbuster Neurontin (gabapentin), interest in the neuropathic pain market has grown exponentially. The market will continue to grow unabated over the next ten years primarily due to increased public and physician awareness and new drug launches, including generic gabapentin.
Scope
Analysis based on The Neuropathic Pain Insight survey of over 594 physicians in the US, Japan, France, Germany, Italy, Spain, and the UK
Referral patterns by indication by country, and treatment of five neuropathic pain types and fibromyalgia
Analysis of the attributes of current treatments, with an overview of late stage pipeline products and physician awareness of these future treatments
Physician perception of strategic issues including clinical trial design, unmet needs, and marketing, and the 'indication versus symptoms' debate
Report Highlights
The current neuropathic pain market suffers from lack of public awareness, poor physician education (often leading to misdiagnosis), under-utilization of effective drugs, inappropriate use of medications, and regional variations in drug availability.
Datamonitor believes the 'indication versus symptoms' debate is one of the most important issues in the current market. Datamonitor recommends existing and potential players consider the pros and cons of regulatory agency viewpoint and rulings across the seven major markets.
Branded products can continue their dominance of the market, supported by aggressive promotional campaigns and astute marketing and product positioning strategies. However, with generic gabapentin entering the market, more than ever companies need to be innovative to effectively define and claim market share.
Reasons to Purchase
Gain a better understanding of the challenges faced by existing and future players in the neuropathic pain market
Predict future trends in the treatment of neuropathic pain and how to capitalize on forthcoming changes in treatment practice
Target lucrative areas of the market as defined by physicians, such as fibromyalgia, and understand why these areas offer commercial opportunity
Region: US, Japan, France, Germany, Italy, Spain, and the UK
Customers who bought this item also bought
Neuropathic Pain Insight - Life Beyond Gabapentin
Pipeline Insight: Neuropathic Pain - Emerging Drugs Fail to Capitalize in Lucrative Market
Peripheral Neuropathy and Neuropathic Pain
US Neuropathic Pain 2008 - 4th Edition: Market Potential Through 2018
Stakeholder Insight: Diabetic Neuropathic Pain - Market Success is Not Limited to Pregabalin
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail To Nail Neuropathic Pain
Strategic Perspectives 2001: Neuropathic pain - Catch 22: high revenue potential but a high risk investment
Neuropathic Pain: Treatments and Prescribing Practices - A Global Survey 2009
Stakeholder Insight: HIV Related Neuropathic Pain - Useful Niche for Peripheral Companies
Commercial Insight: Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities
U.S. Neuropathic Pain Medications Markets
Treatment Algorithms: Cancer Pain - Physician Awareness and Novel Drug Delivery Will Drive Market Opportunities
|
|
|
|
